Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
August 28 2023 - 8:00AM
Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage
biotechnology company developing a pipeline of novel
immunotherapies for the treatment of cancer, today announced
the appointment of Megan Filoon as General Counsel and Dr. Thian
Kheoh as Senior Vice President of Biometrics. Ms. Filoon will
oversee all company legal affairs including corporate governance
and compliance functions. Dr. Kheoh will provide biostatistical
leadership and strategic guidance into the development of the
Company’s product candidate portfolio including the ongoing
AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002.
“Megan and Thian are joining us at an exciting time following
our recent transition to a public company and as we continue to
advance our lead clinical cancer vaccine candidate, ELI-002, for
patients with mKRAS-driven cancers,” said Robert Connelly, Chief
Executive Officer at Elicio Therapeutics. “Megan and Thian further
strengthen an outstanding leadership team and their expertise will
be invaluable in strengthening our legal and compliance functions,
and processing data from our AMPLIFY trials, respectively.”
Megan Filoon most recently served as the General Counsel and
Corporate Secretary for Molecular Templates, Inc., a publicly
traded, oncology-focused biotech, where she was responsible for
providing legal counsel to the company’s board of directors and
management team and advising on corporate governance, securities,
employment, and real estate matters, among other areas. In this
role, Ms. Filoon was responsible for managing the legal, human
resources and administrative departments. She joined Molecular
Templates as Corporate Counsel and during her time there, held
roles of increasing responsibility, becoming General Counsel in
February 2022. Prior to joining Molecular Templates, Ms. Filoon was
a corporate associate at Blank Rome LLP, where she represented
public and private companies in mergers and acquisitions, asset
sales, securities offerings, business formation and corporate
governance matters. She earned her Juris Doctor from Rutgers School
of Law, where she was the Business Editor of the Rutgers Journal of
Law and Public Policy, and her Bachelor of Arts in history and
political science from Boston University.
Thian Kheoh, Ph.D., has over 30 years of drug development and
clinical trial experience in the biopharmaceutical industry. He
most recently served as Vice President of Biometrics at Mirati
Therapeutics where he led the Biometrics team in obtaining the FDA
approval of KRAZATI® for KRAS G12C NSCLC patients. Prior to Mirati,
he held roles of increasing responsibility at Tocagen, Janssen,
Cougar Biotechnology, Biogen-Idec (now Biogen), TAP and Warner
Lambert-Parke Davis. His work focused on exploring the application
of statistical methodologies in preclinical and clinical studies,
introducing novel statistical principles to trial design and
strategic planning to bring effective drugs to cancer patients. Dr.
Kheoh played an integral role in a number of successful global
regulatory submissions and approvals of products that include
ERLEADA®, DARZALEX®, OMNICEF®, SYLVANT®, VELCADE®, YONDELIS®,
ZYTIGA® and the label expansion of RITUXAN®. Before joining the
biopharmaceutical industry, he was an assistant professor at
the University of Central Florida conducting research and
providing lectures in Statistics. Dr. Kheoh earned his Ph.D. from
the University of Western Ontario, Canada.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company
developing a pipeline of novel immunotherapies for the treatment of
cancer. By combining expertise in immunology and immunotherapy,
Elicio is engineering investigational Amphiphile (AMP)
immunotherapies intended to precisely target and fully engage the
lymph nodes, the site in our bodies where the immune response is
orchestrated. Elicio is engineering lymph node-targeted AMPlifiers,
immunomodulators, adjuvants and vaccines for an array of aggressive
cancers.
Cautionary Note on Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, known as the PSLRA. These include
statements regarding Elicio’s planned clinical programs and
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future, and therefore, you are
cautioned not to place undue reliance on them. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Elicio undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by law. We use words such as “anticipates,”
“believes,” “plans,” “expects,” “projects,” “future,” “intends,”
“may,” “will,” “should,” “could,” “estimates,” “predicts,”
“potential,” “continue,” “guidance,” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. Such
forward-looking statements are based on our expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to Elicio’s
plans to research, develop and commercialize its current and future
product candidates.
New factors emerge from time to time, and it is not possible for
us to predict all such factors, nor can we assess the impact of
each such factor on the business or the extent to which any factor,
or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
These risks are more fully discussed in the current report on Form
8-K that was filed with the SEC on June 2, 2023 and Elicio’s
periodic reports and other documents filed from time to time with
the SEC. Forward-looking statements included in this release are
based on information available to Elicio as of the date of this
release. Elicio does not undertake any obligation to update such
forward-looking statements to reflect events or circumstances after
the date of this release, except to the extent required by law.
Media ContactGloria GasaaturaLifeSci
Communicationsggasaatura@lifescicomms.com646-970-4688
Investor Relations ContactHeather
DiVecchiaElicio TherapeuticsIR@elicio.com857-209-0153
Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart
From Sep 2023 to Sep 2024